TH 302

09/02/2010 - "Our data support that hypoxia-activated treatment with TH-302 provides a potential new treatment option for MM."
12/01/2023 - "This study characterized the in vitro potency and hypoxia selectivity of BE-43547 and TH-302. "
12/01/2023 - "BE-43547 is highly hypoxia-selective, and unlike TH-302, displayed minimal variability between cell lines, suggesting that BE-43547 targets a fundamental feature/target that is only present, or of survival importance, during hypoxia. "
11/22/2023 - "In vitro and in vivo experiments confirmed that TH-302 NPs could effectively alleviate tumour hypoxia. "
01/01/2018 - "Cell cycle G2 phase was arrested after treated with 0.05 μmol/L evofosfamide under hypoxia. "

05/21/2015 - "In vivo data demonstrate that Chk1 inhibitor enhances TH-302 anti-tumor activity in p53 mutant HT-29 human tumor xenografts, supporting the hypothesis that these in vitro results can translate to enhanced in vivo efficacy of the combination. "
02/01/2012 - "Tumor-bearing animals breathing 95% O(2) exhibited attenuated TH-302 efficacy, with whereas those breathing 10% O(2) exhibited enhanced TH-302 efficacy, both compared with air (21% O(2)) breathing. "
01/01/2016 - "A web-based literature search was performed through PubMed and Google Scholar using the keywords 'evofosfamide', 'TH-302,' and 'pancreatic tumor.' Of the available results, 53 relevant studies were reviewed and summarized. "
05/21/2015 - "We employed in vitro cell viability, DNA damage, cellular signaling assays and the in vivo HT29 human tumor xenograft model to study the effect of Chk1inhibition on TH-302 antitumor activities. "
02/01/2012 - "The purpose of this study is to characterize the antitumor activity of TH-302 and investigate its selective targeting of the hypoxic cells in human tumor xenograft models. "

01/01/2021 - "The HAP evofosfamide (TH-302) has shown promise in preclinical and early clinical trials of sarcoma. "
01/01/2021 - "Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma."
06/30/2015 - "The combination of TH-302, VEGF-A inhibition, and RT is highly effective in preclinical models of sarcoma and is associated with increased DNA damage and apoptosis in endothelial cells and decreased HIF-1α activity."
01/01/2017 - "Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial."
01/01/2021 - "However, in a phase III clinical trial of non-resectable soft tissue sarcomas, TH-302 did not improve survival in combination with doxorubicin (Dox), possibly due to a lack of patient stratification based on hypoxic status. "

10/01/2017 - "Assessing the efficacy and safety of stereotactic radiation treatment and evofosfamide is warranted in patients with locally advanced pancreatic cancer."
01/01/2016 - "Evofosfamide, a new horizon in the treatment of pancreatic cancer."
01/01/2014 - "TH-302 is a HAP that is currently being evaluated in a Phase III clinical trial in pancreatic cancer. "
05/01/2015 - "This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. "
05/01/2015 - "Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer."

08/01/2018 - "In vitro, neuroblastoma cell line SK-N-BE(2) was 40-folds sensitive to evofosfamide under hypoxia compared to normoxia. "
01/01/2016 - "Evofosfamide shows antitumor effects in neuroblastoma and rhabdomyosarcoma xenografts. "
08/01/2018 - "This study confirms the preclinical efficacy of sunitinib and evofosfamide in murine models of aggressive neuroblastoma. "
08/01/2018 - "Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models."
01/01/2016 - "Neuroblastoma and rhabdomyosarcoma cells were tested in vitro to assess the effect of evofosfamide on cell proliferation, both as a single agent and in combination with topotecan. "